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The purpose of this review is to define animal models of chronic venous disease and to dem-
onstrate how animal studies can impact our understanding and treatment of this disorder. To this
end an extensive literature search was conducted highlighting potential animal models of chronic
lower extremity venous disease. Scientific investigations using animals to study particular as-
pects of this disease are also reviewed. This review was conducted by members of the Com-
mittee on Research of the American Venous Forum to help provide direction for future venous
research endeavors. Useful models of chronic venous occlusive disease involve controlled
ligation of a major lower limb vein and multiple tributaries. Such a model can provide sustained
venous hypertension and studies using this model have confirmed that an isodiametric graft can
provide early hemodynamic relief. Models of primary, postphlebitic, and isolated chronic deep
venous insufficiency are available for study. Valve repair or transplantation can positively impact
the insufficiency observed in these models. Investigations into valve substitutes have generally
been disappointing or are undergoing early evaluation. In conclusion, animal models for the
study of some aspects of chronic venous disease do exist and have already affected our clinical
approach to patients. The scientific study of basic pathophysiology, diagnostics, end-organ
response, and long-term surgical treatments of this disorder in well-controlled animal experi-
ments have not been conducted. (Ann Vasc Surg 1998;12:487-494.)
INTRODUCTION
A clear understanding of the pathophysiology of
lower extremity chronic venous disease is lacking
and one of the major reasons is a deficiency of ani-
mal models that mimic the human condition. As a
result, experimental animal studies to address the
surgical treatment of this problem on a scientific
level have been scarce and substantial clinical ad-
vancement in the treatment of this disorder has
been hindered.
A renewed interest in the study of chronic ve-
nous diseases provides an impetus to review infor-
mation on available animal models. A review of
lessons learned from surgical investigations con-
ducted in these models may provide a glimpse into
what impact such studies have had and may have in
the clinical arena. The direction of future animal
studies is also considered.
LITERATURE REVIEW
Obstructive Models
During the 1970s, the study of extensive acute ve-
nous thrombosis was in full swing. Selective control
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of a canine’s femoral vessels while the remainder of
the leg was subjected to tourniquet occlusion pro-
vided one model of total venous occlusion.1 If the
femoral vein was occluded for 24 hours, one could
expect a 33.3% mortality. Reducing this period of
occlusion to 6 hours followed by femoral vein
declamping resulted in a restoration of arterial flow
without concomitant venous thrombosis. The study
limbs demonstrated severe swelling, ecchymosis,
and approximately 40% of limbs had extensive skin
blebbing. A second canine model required ligation
of all veins from the ipsilateral iliocaval junction to
the femoral vein distal to the profunda including
the contralateral hypogastric vein. The result was a
30% 1-day mortality.2 The high mortality and ex-
tensive limb damage resulting from such model de-
signs were optimal for the study of phlegmasia ce-
rulea dolens but unacceptable for long-term inves-
tigations.
Simple ligation of the femoral vein resulted in a
dramatic increase in peripheral venous pressure im-
mediately following ligation (20-40 torr increase).
This was short-lived, however, in that the pressure
dropped to one-half and then to two-fifths of the
maximal pressure increase within 4 and 72 hours,
respectively.3-5 Simple iliac vein ligation had a simi-
lar fate.6 No venous dilation nor lower limb edema
was noted in these animals. An ipsilateral or cross
femorofemoral vein bypass resulted in the immedi-
ate correction of distal venous hypertension.4,6 A
lack of sustained elevated venous pressure distal to
the ligature in these models was considered a factor
in the overall poor primary patency of attempted
reconstructions (29%).6 Simple ligation of one ma-
jor lower limb vein does not produce sustained dis-
tal venous hypertension necessary for a chronic oc-
clusive model.
A large diameter (1.5 cm) high-flow side-to-side
femoral artery to femoral vein fistula constructed
distal to a femoral vein ligature increased the distal
venous pressure to near arterial levels.7 Although
venous hypertension is generated, this model does
not reflect the clinical condition in that the hyper-
tension is unrelenting and is of uncharacteristic se-
verity.
Controlled ligation of multiple lower extremity
veins provides a more realistic and workable model
of chronic venous hypertension. In a greyhound,
ligation of the external and internal iliac veins in
addition to all side branches to just above the caudal
femoral vein resulted in elevated distal venous pres-
sures at rest and during exercise that was sustained
for at least 15 weeks.8 Lower limb edema resolved
by 6 weeks but there was increased venous pattern-
ing over the lower abdomen. Several short-term
(#4 hours) studies using this model have clarified
some aspects of the surgical treatment of venous
occlusive disease.9-11 Cross femoral vein to femoral
vein bypass of a diameter less than that of the af-
fected limb outflow tract only partially relieves dis-
tal venous hypertension and graft flow is poor.9 The
addition of a distal arteriovenous fistula (dAVF) in-
creased graft flow (∼400 ml/min) but also increased
distal venous hypertension (8-9 times normal).9 An
isodiametric conduit relieved distal venous hyper-
tension.9,10 The addition of a high-flow dAVF
(∼1200 ml/min) was detrimental to venous pres-
sure and induced undesirable physical symptoms.10
A more peripheral dAVF (∼200-400 ml/min) aug-
mented flow without detrimental effects on distal
venous pressures.11 An isodiametric cross femoral
vein bypass using external jugular vein in addition
to a sequential AVF resulted in a normalization of
resting and postexercise distal venous pressures by
6 weeks and maintained this improvement after
AVF ligation (follow-up 6 weeks).8 This model ap-
pears acceptable for investigating several aspects of
the surgical treatment of chronic venous occlusive
disease. Furthermore, studies already performed
with this model clearly suggest that an isodiametric
graft is required to maintain normal venous hemo-
dynamics and that a dAVF of moderate flow may be
helpful to maintain early patency.
Extensive ligation of bilateral hypogastric veins
as well as the external iliac and all branches includ-
ing the superficial femoral vein (SFV) on one side in
a rabbit resulted in elevated distal venous pressures
(∼5 mmHg higher than the normal side) for at least
8 weeks.12 The creation of a small diameter (infe-
rior epigastric vein to side of superficial femoral ar-
tery) dAVF that was ligated after 2 weeks reduced
distal venous pressure postligation by almost one-
half when compared to control limbs. It was theo-
rized that the improvement noted resulted from an
increase in venous collateral size or number. This
model may provide a less costly, yet surgically use-
ful alternative for the study of chronic occlusive
disease.
Insufficiency Models
Primary venous valvular incompetence is a recog-
nized clinical entity. Interestingly, the crossbred
merino sheep have totally or partially incompetent
external jugular vein valves in ∼70% of cases.13
Merely decreasing the valve circumference (∼24%)
with a Venocufft can restore competence. A sug-
gestion that progressive dilation of the vein circum-
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ference may be responsible for some cases of ve-
nous valvular insufficiency was addressed in this
model by creating a 1 cm side-to-side AVF proximal
to a competent valve. With a 45% increase in vein
circumference, all four originally competent valves
became incompetent within 7 days.13
A rat model was used to demonstrate that pro-
longed venous hypertension can lead to valvular
incompetence and eventually complete cusp de-
struction.14 A side-to-side femoral AVF was surgi-
cally constructed and the proximal femoral and epi-
gastric vein were then ligated. There was a 25%
mortality from early cardiac failure. In those sur-
viving, it was observed that the venous valves distal
to the obstruction allowed retrograde flow within 1
day but demonstrated no obvious anatomic alter-
ation. Eventually, however, cusp elongation, sepa-
ration, and leakage were observed. At 4 months, it
was difficult on gross inspection to recognize where
valves had originally been located. This is an ex-
treme hypertensive model which demonstrates
what may happen to veins and their valves when
subjected to prolonged high intravenous pressures.
It is possible that following valve destruction and
subsequent ligation of the fistula, this could be use-
ful as a chronic insufficiency model but the opera-
tive mortality is most likely prohibitive.
Models of chronic venous insufficiency were ini-
tially created by attempting to mimic a thrombo-
phlebitic event. The injection of sclerosing agents
was one such approach. An isolated segment of
femoral vein was emptied of blood and filled with
5% ethanolamine for approximately 5 minutes and
then declamped.15 Only 30% of animals were tech-
nically useful for transplantation due to densely ad-
herent collaterals and surrounding soft tissue in-
flammation. No autogenous valve containing vein
transplant remained patent or competent in short-
term follow-up (Table I). A more mild process was
induced by injecting 1% sotradecol into a 4 cm seg-
ment of ligated femoral vein.16 Transplantation of a
long length (10-19 cm) of valve containing external
jugular vein was accomplished by avoiding the
areas of sclerosis. Continuous patency rates were
not documented and in at least 12% of cases no
valves could be found at sacrifice (Table I). Throm-
bosis of the transplanted venous segment routinely
lead to valvular incompetence. These experiences
lead to the conclusion that a sclerosis model of deep
venous insufficiency has an unpredictable outcome
and is difficult to approach surgically in any event.
Subjecting a major lower limb vein to trauma
and stasis was another method used to create a ve-
nous insufficiency model. This approach involved
isolating a 2.5-4 cm long segment of femoral vein,
emptying it of blood, and then crushing the vein

















5% ethanolamine 15 6–11 30 EJV/CSFV 0 0
1% sotradecol 16 6–8 100* EJV/CSFV 95 NA†
Trauma and stasis 15 6+ 83 CSFV 50 50
15 6+ 83 CSFV 70 65‡
15 Regraft§ NA EJV 40 80‡
17 6+ 98 CSFV 67 39
17 6+ 98 CSFV 100 75‡
Valvulotomy 18-20 3 ∼100 EJV 100 100
18-20 3 ∼100 Experimental/EJV 100 87**
18,19,21†† 3 ∼100 EJV 20 20
18,19,21†† 3 ∼100 EJV 83 83
EJV, external jugular vein; CSFV, contralateral superficial femoral vein.
*Ligated femoral vein; therefore no recanalization possible.
†At least 12% had no valves at sacrifice.
‡24-72 systems therapeutic heparin.
§Only used after original transplant had failed.
**Adjuvant distal arteriovenous fistula.
††Transplant to popliteal vein location.
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with a needle holder. The isolated segment was
filled with blood, bulldog clamps are applied above
and below the area of trauma, and the dogs were
reoperated in 2-4 days to remove the bulldog
clamps.15,17 Recanalization generally resulted in an
acceptable model for venous valve transplantation
(Table I). The addition of 24 hours of perioperative
systemic heparinization to the venous valve trans-
plantation improved the primary patency rate to
∼85% with a reported valve competency rate of
∼70%. Interestingly, if the transplant occluded, re-
grafting with an external jugular vein valve-
containing segment and utilizing 24 hours of sys-
temic heparinization demonstrated a 40% patency
yet a 80% overall competency rate.15 It was impos-
sible to determine if the competent valves noted
after venographically proven graft thrombosis had
actually been involved with the thrombotic process.
It appears that this model may mimic the clinical
situation, can be used for valve transplantation ex-
periments, and may require perioperative and pos-
sibly even prolonged heparinization for optimal re-
sults. A second interesting observation is that not all
venous valves are rendered incompetent when sub-
jected to a thrombotic event.
A greyhound model of lower limb venous valvu-
lar insufficiency with a low model failure rate
(Table I) and uniquely studied by intravenous pres-
sure measurements has been described.18,19 This
model was created by introducing a valvulotome
into the lower limb venous system via a lateral sa-
phenous vein cutdown at the paw and advancing it
proximally into the inferior vena cava. The dog was
then elevated to a standing position and the valvu-
lotome was rapidly pulled distally to disrupt all of
the venous valves. This is a model of isolated deep
venous insufficiency since the greyhound has no
significant superficial or perforator veins nor a large
calf muscle to complicate the picture. The intrave-
nous pressure measurements (venous filling time
[VFT], ambulatory venous pressure [AVP], 90% of
venous refilling time [VRT90]) mimicked tracings
found while studying patients with venous insuffi-
ciency.18,19 Transplanting a competent contralateral
SFV valve-containing vein segment to the SFV lo-
cation on the incompetent side resulted in correc-
tion of the VFT and improvement in the VRT90 but
the AVP was not improved.20 Transplantation of an
external jugular vein (EJV) valve into an incompe-
tent popliteal venous system generally resulted in
thrombosis unless a dAVF was added (Table I).21
With the use of a temporary dAVF (∼750 ml/min),
five of six grafts were patent with normal appearing
valves on gross inspection. The AVP was consistent
with a normal limb and there was improvement of
the VRT90.
21 Using this model it does appear that
venous valve transplantation can impact the ve-
nous hemodynamics of limbs with chronic venous
insufficiency. The final hemodynamic result is de-
pendent upon the location of valve implantation.
The more distal the valve transplant, the greater the
improvement in AVP. Another lesson learned was
that the more distal the valve transplant, the more
critical was the need for an adjuvant dAVF or at
least some adjuvant method to maintain early pa-
tency.
Venous Valve Substitutes
The remaining major surgical study of lower ex-
tremity chronic venous disease in animals has been
a search for a venous valve substitute.
A venous valve constructed from autogenous
vein in the fashion of Eiseman and Malette22 has
been investigated as a substitute for a normal ve-
nous valve of the lower extremity (Table II). The
technique basically involves an intusseption of the
vein into itself with an appropriate cusp made by
two sutures placed at 180° angles from each other
to hold the inner vein wall in the correct posi-
tion.20,23 In all reported studies, only operative hep-
arinization was administered and no long-term an-
ticoagulation was provided. Short-term patency
was excellent with 90%-100% of valves competent
at physiologic pressures. When used to correct the
hemodynamic consequences of chronic venous in-
sufficiency by transplantation to the SFV location,
the VRT90 was improved modestly but not the VFT
that suggested that the valve was not as hemody-
namically responsive as a native valve.20 A modifi-
cation of this type of venous valve involved thin-
ning the adventia and a part of the media to result
in a thin valve cusp after intusseption.24 The valve
opened at a pressure of <3 cm water and closed at a
pressure between 3 and 5 cm of water and could
withstand physiologic pressure changes. Without
the aid of prolonged heparinization, a thin layer of
thrombus along the cusp wall resulted in valve in-
competence. These studies suggest that autog-
enously constructed venous valves may be a rea-
sonable substitute for native valves. However, it
must be cautioned that some of these valves appear
more prone to thrombosis and less responsive in a
hemodynamic sense than is a native valve.
An off-the-shelf valve for use in transplantation
would greatly facilitate the surgical process. At-
tempts to provide such a valve have been investi-
gated (Table II). Transplantation of a valve contain-
ing vein from one dog as a fresh allograft to another
while ignoring rejection issues resulted in failure.17
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Glutaraldehyde preserved allografts even when
supported by a continually functioning dAVF but
became incompetent in short order.25 The umbilical
vein can be frozen, cleaned, and then fitted over an
aluminum mandrel and fixed with glutaraldehyde
to sculpture it into a bicuspid valve.26 All 10 im-
plants failed within 3 days. The same aluminum rod
design was used to fashion liquid pellethane into a
venous valve. All implanted valves clotted in 8
days.26 Platinum or pyrite carbon-covered titanium
center-hinged bileaflet valves have been implanted
into the femoral location of three dogs.27 The pa-
tency and competence of these valves appeared to
be good in early follow-up.27 Two-year results,
however, demonstrated the valves to be rendered
nonfunctional by extensive neointimal hyperpla-
sia.28 The most recent studies have concentrated
again on allografts but preserved by a more gentle
process. Dog erythrocyte antigen (DEA) matched
cryopreserved venous valves have been trans-
planted into canine models with lower limb venous
insufficiency. Supported by a dAVF for 3-6 weeks,
the transplants have remained patent and compe-
tent for ∼3 weeks following dAVF ligation.29 Lower
limb venous hemodynamics were improved similar
to that observed after implantation of an Eiseman/
Malette type valve. No long-term studies are avail-
able for this valve. Even though the cryopreserved
allograft venous valve has shown some early prom-
ise, as yet, all other off-the-shelf prototypes either
preserved allograft or synthetic have not proven to
be a viable substitute for a native venous valve.
























23 SFV SFV 6 100 1-112 days 100 0 250 cm/H2O
E-M* type
valve




24 EJV SFV 6 100 1 week 33 0 300 mmHg









25 SFV SFV 10 80 7 weeks 25 dAVF† —
Cryopreserved 29 SFV SFV 4 50 3 weeks‡ 50 dAVF —
SFV SFV 4 100 3 weeks‡ 100 dAVF —
Heterograft
Glutaraldehyde 26 Umbilical vein Jugular
vein
10 0 3 days 0 Coumadin —
Mandril fitted
Synthetic




10 0 8 days 0 Coumadin 120 mmHg









SFV 3 0 3-24 months 0 0 100 mmHg
SFV, superficial femoral vein; EJV, external jugular vein; dAVF, distal arteriovenous fistula.
*Eiseman-Malette.48
†Adjuvant continuously functioning dAVF.
‡Post dAVF ligation.
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DISCUSSION
The optimal animal model for the study of chronic
venous disease would, of course, exactly mimic the
human condition. The animal would have a natural
propensity for venous thrombosis or primary ve-
nous disease which would translate into obstruc-
tion or insufficiency in a delayed but timely fashion.
A close similarity in the animal’s clotting cascade
and platelet interactions to that of the human
would simplify the study of surgical treatment and
adjuvant postoperative requirements. The animal
would have a lower extremity that closely re-
sembles the human with a functional calf muscu-
lature. Walking upright would be beneficial such
that the sequelae of the disease could be observed
over time. Finally, the animal would be sufficiently
tall (when standing) to allow hemodynamic study
and sufficiently large to allow surgical interven-
tions. This ideal model does not exist.
One of the controversial areas of any animal re-
search involving vascular conduits (bypass grafts,
valve substitutes, etc.) is the coagulation, platelet,
and hematologic differences within mammalian
species. This is an area largely ignored in previous
animal studies of chronic venous disease. There is
information available, however, and one excellent
review considers a majority of these variables for
most species amenable to surgical interventions
from the rabbit to the nonhuman primate.30 In se-
lect areas, one or another species has coagulation
and other hematologic parameters similar to man
and could be selected for study based on this knowl-
edge. Certainly, if one is utilizing the often studied
dog model, normalization of platelet reactivity with
the use of antiplatelet agents would be reasonable31
and has been recognized as important by many in-
vestigators. As the study of valve substitutes using
synthetics or processed allografts becomes more ac-
tive, the study of nonhuman primates may become
imperative to address venous coagulation concerns.
A nonlethal method of testing these materials in
this high-cost model has been reported and should
be considered.32 As our ability to modify the coagu-
lation systems of animals becomes more refined,
less traumatic models of acute deep venous throm-
bosis33 may create animals with chronic disease.
This serendipitous event may provide a more real-
istic model with which to study the sequelae and
surgical treatment of chronic venous disease. A
more in-depth discussion of this topic is beyond the
scope of the current manuscript but certainly any
future research in which thrombosis is such a cru-
cial event must address these concerns.
No current animal model mimics man’s ability to
walk upright nor possess the human calf muscle
pump so important in human venous hemodynam-
ics. Many animals, however, are sufficiently large to
approach surgically and some sufficiently tall to al-
low hemodynamic testing and specific surgeries
such as valve transplantation. It was a learning ex-
perience to find that a greyhound could be used as
a hemodynamic model of venous insufficiency
while the shorter statured mongrel was not appro-
priate since intravenous pressure changes were not
sufficiently different to separate a normal from an
abnormal limb. Certainly, nonhuman primates do
more closely resemble man in some aspect but may
not be appropriate models from a practical stand-
point. The cost of purchase and maintenance must
be considered as must the ease of surgical and an-
esthetic care. Obviously, these factors have cur-
rently made the dog the primary model for the
study of venous surgery. It may be that the throm-
bus-prone canine may be the optimal model for
most research but when specific cardiovascular, co-
agulation or hematologic functions become of pri-
mary concern then other animals including nonhu-
man primates may be more appropriate.
The availability of chronic lower extremity ve-
nous disease models has allowed some in-depth
evaluation of surgical bypass procedures in the
acute setting as enumerated in the body of this
work. However, little research yet exists on the ba-
sic pathophysiology of chronic venous occlusive
disease of the lower extremity. Evaluation of cur-
rent models could provide hemodynamic informa-
tion vital to the manufacture of more precise clini-
cal diagnostic tools. Our lack of ability to precisely
characterize and define this disease has been a ma-
jor clinical obstacle to improved treatment. The
long-term study of venovenous bypass grafts espe-
cially with hemodynamic correlation is still lacking.
This is especially true of synthetic grafts, conduits
prone to thrombosis in the venous system, yet pos-
sibly the only graft of sufficient diameter to correct
the hemodynamic consequences of significant clini-
cal venous occlusive disease.10 Animal models are
particularly well suited for studying such conduits,
modifications to them (e.g., endothelial seeding34 ±
genetic engineering or graft coatings with agents
such as thrombolytics or heparin), and the study of
any potential new materials (e.g., stents,35 specific
polymers). Adjuvants to surgery can also be evalu-
ated in appropriately chosen animal models (e.g.,
low molecular weight heparin, low dose warfarin).
A more in-depth study into the proper size and time
to closure of the often useful dAVF is fruitful
ground for animal investigation. One may also ex-
plore the actual need for bypass grafting in view of
492 Dalsing et al. Annals of Vascular Surgery
the possibility of enhanced collateral size (e.g., an
isolated dAVF,12 drugs to enhance collateral dilata-
tion [nitric oxide36]), or new collateral growth if
veins mimic the response of arteries (vascular en-
dothelial derived growth factor37).
Realizing that animal studies of chronic venous
insufficiency have set the framework for clinical in-
vestigations and have confirmed several clinical im-
pressions, still much remains a mystery and is ame-
nable to animal investigation. A basic understand-
ing of the underlying pathophysiology and
appropriate diagnostic tools for it’s evaluation are
lacking in the clinical arena and can be studied in
appropriate animal models. The proper location of
competent valves in the lower extremity (SFV to
tibial) as well as the need for more than one valve
for the correction of chronic venous insufficiency
requires study. Evaluation of the optimal method to
ensure long-term valve function is a much needed
area of controlled investigation. The optimal size
and time to closure for an adjuvant dAVF can be
more precisely determined. Other adjunctive mea-
sures of potentially more benefit (e.g., low molecu-
lar weight heparin) require experimental consider-
ation. Is external support of valves useful in the
long term or is it detrimental due to local scarring?
The area of valve substitutes is a field conducive to
and requiring animal investigation (e.g., cryopre-
served valves, histocompatible fresh allografts, syn-
thetics ± coatings). These are but a few of the areas
concerning chronic venous insufficiency still await-
ing scientific study.
The area of animal investigation most ignored
but possibly of prime importance is the study of the
end-organ response to chronic venous disease. The
majority of clinical problems associated with deep
venous disease are manifested ultimately in the tis-
sues around the ankle. Edema, skin dermatitis, and
ulceration are three obvious sequelae. Several hy-
pothesis have been proposed to explain the events
leading to these sequelae based upon observations
of the microvascular in humans.38-41 However, to
confirm these hypothesis, research must be per-
formed in an intact living animal where control of
multiple variables is possible. The complex interac-
tions that must take place to result in the final
pathologic condition can be observed in no other
manner. There are models available for the short-
and long-term study of at least some aspects of the
end-organ response to chronic venous occlusive
disease.42-46 Short-term studies of venous insuffi-
ciency could be conducted in the anesthetized up-
right dog.18,19 An animal model of long-term ve-
nous insufficiency with obvious clinical sequelae in
the lower extremity is presently elusive. Such stud-
ies are basic to our understanding of the impact of
venous disease on the lower leg and to allow some
method of formulating potential treatments to
modify it. We need to know the histological and
functional effect of this disease on large to small
arterioles, venules, capillaries, lymphatics, skin,
muscle, and subcutaneous tissue. Does chronic ve-
nous disease eventually lead to lymphatic destruc-
tion and little chance of permanent cure? What im-
pact does chronic venous disease have on blood-
born products entering the limb (e.g., white cells,
platelets, macromolecules) and how is the intersti-
tial fluid and the matrix in which it lies altered?
What effect do different drugs have on these adap-
tations to the disease state (e.g., pentoxyfilline47)?
What effect does surgical treatment have on the
end-organ at various stages of the disease? Would
earlier intervention prevent a progression of the
disease process to a state of no return?
This review provides a historical perspective of
the animal models available for the study of lower
limb chronic venous disease. Previous studies using
these models have directed and continued to direct
the surgical care of this disorder. However, most
aspects of chronic venous disease have not been
studied by the scientific method and it appears that
animal models are often indispensable to these in-
vestigations. It is hoped that bright young minds
will choose to address some of the very difficult
questions that remain concerning a very old yet
very misunderstood disorder.
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